AbbVie Inc. ($ABBV) Stock Forecast: Down 0.2% Today

What is AbbVie Inc.?

Stock: ABBV A pharmaceutical company known for its popular drugs like Humira, Skyrizi, and Rinvoq has been expanding its product portfolio to drive revenue growth.

Why is AbbVie Inc. going down?

ABBV stock is down 0.2% on Jul 31, 2025 17:56

• AbbVie reported strong Q2 sales growth and raised its 2025 earnings outlook, but the stock faced downward pressure.
• Market reaction to the company missing EPS estimates despite exceeding sales expectations may be a factor.
• Concerns about the potential impact of Humira's future decline on revenue growth, despite growth in Skyrizi and Rinvoq, are looming.
• AbbVie's stock movement may have been influenced by the overall performance of the pharmaceutical industry, with upcoming earnings releases from other key players like MRK, AZN, BMY, and MRNA.

ABBV Price Chart

ABBV Technical Analysis

ABBV News

Why Is AbbVie Stock Gaining On Thursday? - AbbVie ( NYSE:ABBV )

AbbVie Q2 sales hit $15.42 billion vs. $14.98 billion estimate, driven by strong Skyrizi and Rinvoq performance. EPS rose 12% Y/Y to $2.97, missing $3.23 estimate; AbbVie raised its 2025 earnings outlook to $11.88-$12.08. Get special access to three exclusive "Top 10 Stocks" power lists today, ...

https://www.benzinga.com/markets/earnings/25/07/46762357/abbvie-lifts-outlook-eyes-parkinsons-assets-as-next-growth-frontier

AbbVie ( ABBV ) Tops Q2 Earnings and Revenue Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of +2.77% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2643359/abbvie-abbv-tops-q2-earnings-and-revenue-estimates

Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?

ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.

https://www.zacks.com/stock/news/2629288/pre-q2-earnings-is-abbvie-stock-a-portfolio-must-have

Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?

Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.

https://www.zacks.com/stock/news/2629094/will-these-5-pharmabiotech-bigwigs-surpass-q2-earnings-forecasts

Trending Today

Monero ($XMR) Crypto Forecast: Down 5.2% Today

Bitcoin Cash ($BCH) Crypto Forecast: Down 5.4% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 5.2% Today

Ethereum ($ETH) Crypto Forecast: Down 5.6% Today

Amazon.com Inc. ($AMZN) Stock Forecast: Down 8.2% Today

Pacific Gas & Electric Co. ($PCG) Stock Forecast: Up 2.2% Today

LyondellBasell Industries NV Class A (Netherlands) ($LYB) Stock Forecast: Down 6.8% Today

Peloton Interactive Inc ($PTON) Stock Forecast: Down 7.4% Today

Avantor, Inc. ($AVTR) Stock Forecast: Down 17.0% Today

Ethena ($ENA) Crypto Forecast: Down 5.2% Today

AbbVie Inc. Price History

04.03.2025 - ABBV Stock was down 5.2%

• The stock has seen a 16% rise year to date, indicating a positive trend overall.
• Unusual options activity today showed investors taking a bearish stance on AbbVie, possibly contributing to the bearish movement.
• Despite this, deep-pocketed investors have recently adopted a bullish approach towards AbbVie, suggesting conflicting sentiments in the market.
• The overall market sentiment seems mixed, with potential profit-taking by some investors and optimism about the company's future growth prospects.

12.04.2025 - ABBV Stock was up 5.4%

• Despite ongoing legal issues involving Cerevel Therapeutics Holdings, Inc. (linked to ABBV), AbbVie's stock remained unaffected, demonstrating investor confidence in the company's strength.
• Representative Marjorie Taylor Greene's significant acquisition of AbbVie shares likely played a role in enhancing market sentiment and contributing to the stock's positive movement.
• Investor focus appears to be primarily on AbbVie's performance and growth potential within the pharmaceutical sector, overshadowing the legal troubles of other related companies.
• The market's favorable response to the insider trading news and the overall bullish performance indicates investor optimism regarding AbbVie's future, despite legal uncertainties surrounding associated firms.

12.04.2025 - ABBV Stock was up 5.2%

• Uncommon options behavior indicated a positive outlook on AbbVie, attracting investor attention and contributing to the bullish trend.
• Reports of substantial AbbVie stock acquisitions by legislators may have boosted confidence in the company's future, driving up buying interest.
• Despite ongoing legal challenges, the positive publicity surrounding influential individuals investing in AbbVie likely overshadowed any potential negativity, pushing the stock price up.
• The optimistic options activity and significant stock acquisitions by government officials probably fostered a favorable outlook on AbbVie, prompting the bullish movement in the market.

15.00.2025 - ABBV Stock was down 0.9%

• The stock of AbbVie has seen a significant decline in the past three months, prompting investors to evaluate whether to buy, hold, or sell their positions. This downward trend may have contributed to today's bearish movement.
• The partnership announcement with Simcere Zaiming to develop a novel trispecific antibody candidate in multiple myeloma could have initially sparked investor interest. However, the market reaction to this news seems to have been overshadowed by broader market conditions or other factors.
• Despite the positive sentiment from unusual options activity indicating a bullish approach towards AbbVie, the stock still faced a notable decline today. This discrepancy between investor sentiment and market performance suggests that external factors or broader industry trends might be influencing AbbVie's stock movement.

15.04.2025 - ABBV Stock was down 5.0%

• The FDA fast-tracking AbbVie's new lung cancer therapy, Emrelis, may have sparked concerns among investors regarding the company's ability to meet high expectations, leading to profit-taking and a bearish trend.
• Unusual options activity indicating a bullish stance possibly initially boosted the stock, but the subsequent decline could suggest a shift in sentiment or profit realization by investors.
• The class action lawsuit against Cerevel Therapeutics Holdings, Inc., a company linked to AbbVie, likely created uncertainty and negative sentiment around AbbVie, contributing to the bearish movement.
• Representative Jared Moskowitz's significant purchase of AbbVie stock may have been viewed as a positive sign initially, but the overall market sentiment possibly overshadowed this, resulting in the bearish movement.

14.04.2025 - ABBV Stock was down 5.1%

• The bearish movement in AbbVie's stock price today could be attributed to profit-taking by investors after a recent increase in the stock value over the past month and year.
• The unusual options activity showing a bullish stance on AbbVie might indicate conflicting sentiments among investors, leading to increased volatility and potential sell-offs.
• The news of a Congressional report revealing a purchase of AbbVie stock by Representative Jared Moskowitz could have influenced market sentiment, but the overall impact on the stock price remains uncertain.
• The class action lawsuit notification against Cerevel Therapeutics Holdings, Inc. (ABBV) could have created negative sentiment around the pharmaceutical sector, impacting AbbVie's stock price negatively.

31.00.2025 - ABBV Stock was up 6.1%

• AbbVie's strong bullish movement today is linked to its Q4 earnings and sales performance surpassing expectations and an increased sales forecast for key drugs like Skyrizi and Rinvoq.
• The market reacted positively to AbbVie's revenue growth, particularly due to the success of newer immunology drugs that offset the decline in Humira sales.
• Investor confidence in AbbVie's future appears high, evident in the company's market outperformance over the past 5 years and the raised revenue forecast for key drugs.
• AbbVie's focus on innovative drugs and robust financial performance have been key drivers of its bullish movement today, reflecting investor confidence in the company's growth trajectory.

31.00.2025 - ABBV Stock was up 7.7%

• AbbVie surpassed Q4 earnings projections, primarily driven by robust sales of Skyrizi and Rinvoq leading to revenue growth.
• The company increased its revenue forecast for Skyrizi and Rinvoq for 2027, reflecting a high level of confidence in the performance of these medications.
• The market displayed optimism towards AbbVie's future prospects, as demonstrated by today's bullish movement in the stock.
• Emphasis on the sales figures of critical drugs like Rinvoq and Skyrizi preceding the earnings announcement likely influenced the positive market sentiment surrounding AbbVie.

31.00.2025 - ABBV Stock was up 7.5%

• AbbVie's favorable market movement today is driven by optimistic projections for its immunology division, anticipating growth rates of 7% in 2025 and 10-11% in 2026-2027.
• Shareholders are eagerly anticipating AbbVie's Q4 financial results, especially focusing on the sales performance of Rinvoq and Skyrizi, which serve as pivotal growth catalysts for the company.
• Analysts have raised AbbVie's price target to $208, instilling further confidence among investors.
• A comparison of technical indicators with Novartis reveals AbbVie's current stability leading up to its earnings announcement. However, identified resistance levels exceeding $177 could potentially trigger positive market sentiment following the report.

06.04.2025 - ABBV Stock was down 5.1%

• A class action securities lawsuit involving ABBV and Cerevel Therapeutics Holdings, Inc. has raised concerns among investors about potential legal risks and financial implications for AbbVie.
• AbbVie was mentioned in a program alongside Netflix and Sherwin-Williams, possibly leading to comparisons in performance and highlighting any weaknesses or challenges faced by AbbVie.
• The bearish movement in AbbVie's stock may be a reaction to negative sentiment in the pharmaceutical sector or specific company-related issues.

12.05.2025 - ABBV Stock was down 2.4%

• Despite positive FDA approval for Mavyret in pediatric patients with Hepatitis C and a significant purchase of AbbVie stock by Rep. Robert Bresnahan, the stock experienced a bearish movement.
• The market may have reacted negatively to concerns about AbbVie's ability to offset the sales drop post-U.S. patent loss of Humira, despite the expected growth from Skyrizi and Rinvoq.
• The overall market dip could have also contributed to AbbVie's bearish movement, as seen in the increase in stock price despite the market slip.
• Investors might be cautious about the company's future revenue streams and competitive positioning in the pharmaceutical industry, leading to the bearish trend in AbbVie's stock price.

31.06.2025 - ABBV Stock was down 0.2%

• AbbVie reported strong Q2 sales growth and raised its 2025 earnings outlook, but the stock faced downward pressure.
• Market reaction to the company missing EPS estimates despite exceeding sales expectations may be a factor.
• Concerns about the potential impact of Humira's future decline on revenue growth, despite growth in Skyrizi and Rinvoq, are looming.
• AbbVie's stock movement may have been influenced by the overall performance of the pharmaceutical industry, with upcoming earnings releases from other key players like MRK, AZN, BMY, and MRNA.